<DOC>
	<DOC>NCT01845623</DOC>
	<brief_summary>This study will assess the pharmacodynamics, safety, tolerability and pharmacokinetics of indacaterol maleate (QAB149), administered via the EPIC test fixture. The study aims to determine whether the novel device has a similar clinical profile as the established concept 1 device.</brief_summary>
	<brief_title>A Study to Evaluate the Effects of Indacaterol Maleate (QAB149) as a New Formulation in the EPIC Test Fixture</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Male and female patients with asthma, aged 18 or above Patients using inhaled corticosteroid (with or without long acting beta agonist) Patients who demonstrate an increase in FEV1 after inhaling a short acting beta agonist Asthma exacerbations in previous 6 months COPD or other pulmonary disease Excessive use of short acting beta agonists Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Indacaterol</keyword>
	<keyword>QAB149</keyword>
</DOC>